Risk of peptic ulcer bleeding associated with Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs, low-dose aspirin, and antihypertensive drugs: A case-control study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 2, 2015, Pages 292-298

  Nagata, Naoyoshi ^a   Niikura, Ryota ^a   Sekine, Katsunori ^a   Sakurai, Toshiyuki ^a   Shimbo, Takuro ^a   Kishida, Yoshihiro ^a   Tanaka, Shohei ^a   Aoki, Tomonori ^a   Okubo, Hidetaka ^a   Watanabe, Kazuhiro ^a   Yokoi, Chizu ^a   Akiyama, Junichi ^a   Yanase, Mikio ^a   Mizokami, Masashi ^b   Uemura, Naomi ^b  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b National Center for Global Health and Medicine   (Japan)

Author keywords

Acetylsalicylic acid; Bleeding ulcer; helicobacter pylori; Interaction; Non variceal upper gastrointestinal bleeding

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HELICOBACTER INFECTION; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; INFECTION RISK; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; ADVERSE EFFECTS; COMPLICATION; DRINKING BEHAVIOR; GASTRITIS; HELICOBACTER PYLORI; MICROBIOLOGY; MIDDLE AGED; PEPTIC ULCER HEMORRHAGE; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; ASPIRIN; CASE-CONTROL STUDIES; FEMALE; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER HEMORRHAGE; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84921527797     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12805     Document Type: Article

References (35)

1. Rothwell PM, Algra A, Amarenco P. Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke. Lancet 2011; 377: 1681-1692.
2. Pahor M, Guralnik JM, Furberg CD, Carbonin P, Havlik R. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996; 347: 1061-1065.
3. Smalley WE, Ray WA, Daugherty JR, Griffin MR. No association between calcium channel blocker use and confirmed bleeding peptic ulcer disease. Am. J. Epidemiol. 1998; 148: 350-354.
4. Kelly JP, Laszlo A, Kaufman DW, Sundstrom A, Shapiro S. Major upper gastrointestinal bleeding and the use of calcium channel blockers. Lancet 1999; 353: 559.
5. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment. Pharmacol. Ther. 2002; 16: 779-786.
6. Shiotani A, Nishi R, Yamanaka Y etal. Renin-angiotensin system associated with risk of upper GI mucosal injury induced by low dose aspirin: renin angiotensin system genes' polymorphism. Dig. Dis. Sci. 2011; 56: 465-471.
7. Shiotani A, Sakakibara T, Yamanaka Y etal. Upper gastrointestinal ulcer in Japanese patients taking low-dose aspirin. J. Gastroenterol. 2009; 44: 126-131.
8. Kaplan RC, Heckbert SR, Koepsell TD, Rosendaal FR, Psaty BM. Use of calcium channel blockers and risk of hospitalized gastrointestinal tract bleeding. Arch. Intern. Med. 2000; 160: 1849-1855.
9. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288: 2981-2997.
10. Lanas A, Garcia-Rodriguez LA, Arroyo MT etal. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731-1738.
11. Lanas A, Garcia-Rodriguez LA, Arroyo MT etal. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am. J. Gastroenterol. 2007; 102: 507-515.
12. Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177: 347-351.
13. Hallas J, Dall M, Andries A etal. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006; 333: 726.
14. Lanza FL, Chan FK, Quigley EM. Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am. J. Gastroenterol. 2009; 104: 728-738.
15. Wu CY, Poon SK, Chen GH, Chang CS, Yeh HZ. Interaction between Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer bleeding. Scand. J. Gastroenterol. 1999; 34: 234-237.
16. Sakamoto C, Sugano K, Ota S etal. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur. J. Clin. Pharmacol. 2006; 62: 765-772.
17. Kang JM, Kim N, Lee BH etal. Risk factors for peptic ulcer bleeding in terms of Helicobacter pylori, NSAIDs, and antiplatelet agents. Scand. J. Gastroenterol. 2011; 46: 1295-1301.
18. Fock KM, Ang TL. Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. J. Gastroenterol. Hepatol. 2010; 25: 479-486.
19. Uemura N, Okamoto S, Yamamoto S etal. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001; 345: 784-789.
20. Sturmer T, Brenner H. Potential gain in precision and power by matching on strong risk factors in case-control studies: the example of laryngeal cancer. J. Epidemiol. Biostat. 2000; 5: 125-131.
21. Nagata N, Niikura R, Aoki T etal. Lower GI bleeding risk of nonsteroidal anti-inflammatory drugs and antiplatelet drug use alone and the effect of combined therapy. Gastrointest. Endosc. 2014; pii: S0016-5107(14)01930-0. doi: 10.1016/j.gie.2014.06.039. [Epub ahead of print].
22. Nagata N, Niikura R, Aoki T etal. Colonic diverticular hemorrhage associated with the use of NSAIDs, low-dose aspirin, antiplatelet drugs, and dual therapy. J. Gastroenterol. Hepatol. 2014; 29: 1786-1793.
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 1987; 40: 373-383.
24. Crooks CJ, West J, Card TR. Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding. Gastroenterology 2013; 144: 1384-1393. 1393.e1-2; quiz e18-9.
25. Tu TC, Lee CL, Wu CH etal. Comparison of invasive and noninvasive tests for detecting Helicobacter pylori infection in bleeding peptic ulcers. Gastrointest. Endosc. 1999; 49: 302-306.
26. Colin R, Czernichow P, Baty V etal. Low sensitivity of invasive tests for the detection of helicobacter pylori infection in patients with bleeding ulcer. Gastroenterol. Clin. Biol. 2000; 24: 31-35.
27. Lanas A, Bajador E, Serrano P etal. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N. Engl. J. Med. 2000; 343: 834-839.
28. Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin. Gastroenterol. Hepatol. 2006; 4: 130-142.
29. Chan FK, Ching JY, Suen BY, Tse YK, Wu JC, Sung JJ. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 2013; 144: 528-535.
30. Gisbert JP, Calvet X, Cosme A etal. Long-term follow-up of 1000 patients cured of Helicobacter pylori infection following an episode of peptic ulcer bleeding. Am. J. Gastroenterol. 2012; 107: 1197-1204.
31. de Groot NL, Hagenaars MP, Smeets HM, Steyerberg EW, Siersema PD, van Oijen MG. Primary non-variceal upper gastrointestinal bleeding in NSAID and low-dose aspirin users: development and validation of risk scores for either medication in two large dutch cohorts. J. Gastroenterol. 2014; 49: 245-253.
32. Uemura N, Sugano K, Hiraishi H etal. Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study. J. Gastroenterol. 2014; 49: 814-824.
33. Nadatani Y, Watanabe T, Tanigawa T etal. Incidence and risk factors of gastrointestinal bleeding in patients on low-dose aspirin therapy after percutaneous coronary intervention in Japan. Scand. J. Gastroenterol. 2013; 48: 320-325.
34. Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am. J. Gastroenterol. 2014; 109: 811-819.
35. Verhamme K, Mosis G, Dieleman J, Stricker B, Sturkenboom M. Spironolactone and risk of upper gastrointestinal events: population based case-control study. BMJ 2006; 333: 330.